Hepatic Cell News 2.13 April 13, 2018 | |
| |
TOP STORYBased on deep sequencing and quantitative PCR, researchers found that higher level of serum miR‐103 was associated with higher metastasis potential of hepatocellular carcinoma. [Hepatology] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors investigated the effects of dysregulated glutathione homeostasis, a principal feature of oxidative stress, on tumor necrosis factor-α (TNFα)-induced hepatotoxicity and its mechanistic implications in non-alcoholic fatty liver disease progression. [Exp Mol Med] Full Article Investigators found a novel signaling transduction mechanism between oncogenic hepatocytes and hepatic stellate cells. After krasV12 induction, fibrinogen was up-regulated in oncogenic hepatocytes. [Neoplasia] Full Article The impact of the co-exposure to the environmental carcinogen benzo[a]pyrene and the lifestyle-related hepatotoxicant ethanol, was tested on in vitro models of steatosis and on an in vivo model. [Sci Rep] Full Article Scientists synthesized novel paullone-like scaffolds, IFBOs, and screened them against hepatocellular carcinoma (HCC) specific Hep-G2 cells. Three of the synthesized compounds significantly attenuated the progression of HCC in vitro. [Sci Rep] Full Article NEDD4 Promotes Cell Growth and Motility in Hepatocellular Carcinoma NEDD4 acted as an oncoprotein in both QGY7703 and SMMC7721 liver cancer cell lines. Researchers found that depletion of neuronally expressed developmentally downregulated 4 (NEDD4) by siRNA transfection led to inhibition of cell growth, invasion and migration, and promotion of apoptosis. [Cell Cycle] Abstract Role of Mitophagy Regulation by ROS in Hepatic Stellate Cells during Acute Liver Failure In vivo observations revealed that superoxide dismutase 2 immunostaining was increased in acute liver failure patients and mice models, and in vitro experiments demonstrated that LPS/reactive oxygen species promoted inflammation via inhibiting mitophagy. Moreover, the regulation of inflammation was apoptosis independent in hepatic stellate cells. [Am J Physiol Gastrointest Liver Physiol] Abstract CD147 Promotes CXCL1 Expression and Modulates Liver Fibrogenesis Scientists showed an important role of CD147 in promoting liver fibrosis by activating hepatic stellate cells (HSCs) and upregulating expression of chemokines. They found that CD147 specific deletion in HSCs mice alleviated CCl4-induced liver fibrosis and inhibited HSCs activation. [Int J Mol Sci] Full Article The authors investigated the involvement of downstream mevalonate products that mediate the anti-oxidant and anti-proliferative effects of atorvastatin, and its effect on miRNA-145 expression in HepG2 hepatocellular carcinoma cells. [Chem Biol Interact] Abstract | |
| |
REVIEWSAugmenter of Liver Regeneration: A Key Protein in Liver Regeneration and Pathophysiology This review brings a concise presentation of the work done till now in the areas exploring role of augmenter of liver regeneration in normal liver physiology and in liver health maintenance by fighting liver diseases, such as liver failure, NAFLD/NASH, viral infections, cirrhosis and hepatocellular carcinoma. [Hepatol Res] Abstract Visit our reviews page to see a complete list of reviews in the hepatic cell research field. | |
| |
SCIENCE NEWSCan-Fite BioPharma Ltd. announced its poster presentation of the anti-inflammatory and anti-fibrogenic effects of Namodenosen in NAFLD/NASH animal model data. [Press release from Can-Fite BioPharma Ltd. discussing research presented at the 53rd Annual International Liver Congress of the European Association for the Study of the Liver (EASL), Paris] Press Release Enanta to Present New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH Enanta Pharmaceuticals, Inc. announced that data from Enanta’s wholly-owned development programs, including EP-027367, one of Enanta’s novel core inhibitors in preclinical testing targeting hepatitis B virus, and EDP-305, an FXR agonist in development for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis, will be presented. [Press release from Enanta Pharmaceuticals, Inc. discussing research presented at the 53rd Annual International Liver Congress of the European Association for the Study of the Liver (EASL), Paris] Press Release Gilead Sciences, Inc. presented data from a proof-of-concept study of investigational combination therapies for patients with advanced fibrosis due to NASH, combining the apoptosis signal-regulating kinase 1 inhibitor selonsertib with either the acetyl-CoA carboxylase inhibitor GS-0976 or the selective, non-steroidal farnesoid X receptor agonist GS-9674. [Press release from Gilead Sciences, Inc. discussing research presented at the 53rd Annual International Liver Congress of the European Association for the Study of the Liver (EASL), Paris] Press Release MediciNova, Inc. presented the positive results from the interim analysis of the Phase II clinical trial of MN-001 in non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia. [Press release from MediciNova, Inc. discussing research presented at the 53rd Annual International Liver Congress of the European Association for the Study of the Liver (EASL), Paris] Press Release Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data Arrowhead Pharmaceuticals Inc. announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of chronic hepatitis B infection. [Press release from Arrowhead Pharmaceuticals Inc. discussing research presented at the 53rd Annual International Liver Congress of the European Association for the Study of the Liver (EASL), Paris] Press Release Promethera Biosciences SA presented novel preclinical data on its development program HepaStem. Building on previously generated data in early stage nonalcoholic steatohepatitis (NASH), the new data demonstrates for the first time the cell-based therapy’s ability to improve key disease parameters in a proven model for advanced stage of the disease. [Press release from Promethera Biosciences SA discussing research presented at the 53rd Annual International Liver Congress of the European Association for the Study of the Liver (EASL), Paris] Press Release | |
| |
INDUSTRY NEWSIonis and AstraZeneca Advance New Drug for NASH Ionis Pharmaceuticals, Inc. announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca following advancement of the drug into development. [Ionis Pharmaceuticals, Inc.] Press Release Ipsen announced that the European Medicines Agency (EMA), the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx®, for patients with previously treated advanced HCC. [Ipsen] Press Release Celsion Corporation announced that the independent DMC for the company’s 550-patient, multinational, double-blind, placebo-controlled, pivotal Phase III clinical study of ThermoDox® in combination with radiofrequency ablation for primary liver cancer (the OPTIMA Study), has unanimously recommended that the study continue according to protocol to its data readout. [Celsion Corporation (GlobeNewswire)] Press Release BeiGene, Ltd. announced that the first patient was dosed in a global Phase II clinical trial of tislelizumab, an investigational anti-PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma. [BeiGene, Ltd.] Press Release | |
| |
POLICY NEWSThe March for Science Is Back — and Here’s What to Expect Nature takes a look at why people are marching, how the movement has changed over time and what its future could bring. [Nature News] Editorial Spain’s Biggest-Ever Science Petition Decries ‘Abandonment’ of Research Leading Spanish scientific organizations delivered a petition signed by more than 277,000 people to the national parliament in Madrid, calling on the government to stop the “progressive abandonment of science in Spain” caused by budget cuts. The petition is the largest ever on a science-policy subject in Spain. [Nature News] Editorial Panel Calls for a Postdoc Tax and Other Measures to Help Biomedical Scientists Find Jobs The U.S. Congress, federal funding agencies, universities, and other research institutions must take significant steps, such as a postdoc “tax” and a hard cap on how long postdocs can be funded by a lab head, to better usher young biomedical scientists into viable careers, a committee from the National Academies of Sciences, Engineering, and Medicine concluded in a report. [ScienceInsider] Editorial
| |
EVENTSNEW LabRoots: 6th Annual Cancer Research & Oncology Virtual Event Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – Liver Cancer and Epigenetics (International Clinical Research Center) NEW Research Fellow – Liver Tumorigenesis (Harvard School of Dental Medicine) Postdoctoral Fellow – Alcoholic Liver Disease (University of North Carolina at Greensboro) Assistant/Associate Professor – Virology (Saint Louis University School of Medicine) Postdoctoral Position – Cancer, Immunotherapy, and Fibrosis (University of Alabama at Birmingham) Postdoctoral Fellow – Human Liver Function (Karolinska Institutet) Postdoctoral Research Associate – Hepatitis B Virology (Imperial College London) Postdoctoral Research Associate – Liver Diseases (University of Illinois at Chicago) Postdoctoral Scientist – Acute-on-Chronic Liver Failure (Foundation for Liver Research) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hepatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|